肝硬化

Liver cirrhosis 21

Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension 23

Keep beta-blocking and carry on! 24

Carvedilol as Best β-Blocker for Secondary Prophylaxis of Variceal Bleeding: Are We There, or Not Yet? 23

Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: a national cohort study 23

AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis 24

AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage 24

Inpatient management of fluid overload (ascites, hepatic hydrothorax, and anasarca) 24

Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?

Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review 24

肝癌

Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines 24

The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis 24

Unmet needs in the post-DAA era: the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication 24

British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults  24

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update 24

The impact of hepatitis C virus cure on hepatocellular carcinoma occurrence and outcomes 24

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma 23